Generic for Revlimid was listed as the lowest price

In four years after approval

It is differentiated from other products in the 50,000 won range and 70,000 to 80,000 won range, such as Samyang Holdings

Generic drugs, not enough for the original., pay attention to changes in the market

Boryung Pharmaceutical is launching a generic drug called Revlimid (Renalidomide) for multiple myeloma treatment after four years of approval.

 

With three general companies targeting the market since 2018, Boryung has thrown a winning move at the lowest price.

 

According to the contents of the "Partial revision of the drug benefit list and upper limit table" released by the MOHW on the 21st, four capacities of Boryung Pharmaceutical's generic for Revlimid will be listed from March 1.

 

It has been about four years since it was first approved in June 2018 with 25 mg.

 

Generic for Revlimid has been on the market since January 2018.

 

Currently, Chong Kun Dang's Lenaloma, Kwang Dong Pharmaceutical's Lenaldo, and Samyang Holdings' Lenalid are competing with the original drug Revlimid of Celgene.

 

Generic drugs have yet to exert much power in the market.

 

Quarterly sales of original products are around 8 billion won, but generic drugs alone maintain around 1 billion won.

 

According to IQVIA in the second quarter of last year, Celgene's Revlimid recorded 8.8 billion won, Chong Kun Dang's Lenaloma recorded 1 billion won, Kwang Dong's Lenaldo 75.42 million won, and Samyang's Lenalid recorded 143.41 million won.

 

Generic drugs are showing price competitiveness as a weapon against their original status, but it is not easy.

 

Comparing the upper limit based on the 10mg formulation, Samyang's Lenalid costs 51,472 won, Chong Kun Dang's Lenaloma costs 71,874 won, Celgene's Revlimid costs 84,975 won, and Kwang Dong's Lenaldo costs 86,000 won.

 

Compared to the original, Samyang's Lenalid is 20,000 won cheaper, and Chong Kun Dang's Lenaloma is 10,000 won cheaper.

 

Boryung also chose the lowest price.

 

Leblikin10mg is 51,471 won, 1 won cheaper than the current lowest price, Lenalid in Samyang.

 

In particular, it is expected that it will be able to show competitiveness because it is 20,000 won to 30,000 won cheaper than existing products among capsule formulations.

 

Boryung is preparing a variety of new products with generic for Revlimid to target the market for treating multiple myeloma.

 

It is on the verge of developing the first generic of the latest version of Celgene's Pomalyst following Revlimid, and plans to introduce a new drug called Aplidin (Plitidepsin), Aplidin signed a contract with Spanish pharmaceutical company PharmaMar in 2016 to secure domestic copyright.

 

Only Janssen's generic for Velcade(Bortezomib) Velkin was sold.

 

Attention is focusing on whether Boryung will show the power of domestic pharmaceutical companies in the anticancer drug market with the lowest price strategy put forward along with various product lines.